Creutzfeldt-Jakob Disease

Pharma company finds way to remove prions that cause mad cow in humans

Published in Medical Letter on the CDC and FDA, March 13th, 2005

Assessing the risk of potential exposure to variant Creutzfeldt-Jakob Disease (vCJD), the human form of "mad cow disease," from blood transfusion was the focus of the U.S. Food & Drug Administration (FDA) transmissible spongiform encephalopathies (TSEs) advisory committee in Silver Spring, Maryland.

In response to the committee's encouragement that new technologies should be considered that might lead to greater reduction of risk while not deferring many donors unnecessarily, Pall Corporation (NYSE:PLL) presented the latest scientific data on its new prion reduction technology. The Leukotrap Affinity Prion Reduction Filter, expected to be launched commercially in Europe...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-03-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry